We are live on ! Find out more
PPBT

Purple Biotech
PPBT

10 hedge funds and large institutions have $946K invested in Purple Biotech in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more capital invested

Capital invested by funds: $776K → $946K (+$170K)

4.13% more ownership

Funds ownership: 6.75% → 10.88% (+4.1%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

47% less funds holding

Funds holding: 19 → 10 (-9)

82% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 11

Holders
10
Holders Change
-9
Holders Change %
-47.37%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
1
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$680K
2
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$27.8K
3
TRCT
Tower Research Capital (TRC)
New York
+$1.89K

Top Sellers

Rank Fund Capital Flow
1
KWA
Kingswood Wealth Advisors
California
-$84.7K
2
Morgan Stanley
Morgan Stanley
New York
-$15.8K
3
Citadel Advisors
Citadel Advisors
Florida
-$10.2K
4
VVP
Venture Visionary Partners
Ohio
-$9.02K
5
VF
Virtu Financial
New York
-$8K

PPBT Hedge Fund Activity: Q3 2024 in Review

10 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q3 2024, worth a combined $946K — up 22% from $776K a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of PPBT and 2 opened new positions — a net loss of 9 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Armistice Capital, adding an estimated $680K. The largest seller was Kingswood Wealth Advisors, exiting entirely with an estimated $84.7K sold.

  • 10 institutional investors held Purple Biotech (PPBT) as of Q3 2024, down from 19 in Q2 2024.
  • Funds reported $946K of Purple Biotech stock for Q3 2024, up 22% quarter-over-quarter.
  • 2 funds opened new Purple Biotech positions in Q3 2024 and 11 closed out, a net change of -9 holders.
  • The largest Purple Biotech buyer in Q3 2024 was Armistice Capital, an estimated $680K added.
  • The largest Purple Biotech seller in Q3 2024 was Kingswood Wealth Advisors, an estimated $84.7K sold.

Based on aggregated 13F filings for Q3 2024.